Salud financiera de hoja de balance de Bio-Rad Laboratories
Salud financiera controles de criterios 5/6
Bio-Rad Laboratories tiene un patrimonio de accionistas total de $7.5B y una deuda total de $1.2B, lo que sitúa su ratio deuda-patrimonio en 15.9%. Sus activos y pasivos totales son $10.6B y $3.1B respectivamente. El BAIT de Bio-Rad Laboratories es de $333.9M, por lo que su ratio de cobertura de intereses es de -9.9. Tiene efectivo e inversiones a corto plazo que ascienden a $1.6B.
Información clave
15.9%
Ratio deuda-patrimonio
US$1.19b
Deuda
| Ratio de cobertura de intereses | -9.9x |
| Efectivo | US$1.62b |
| Patrimonio | US$7.49b |
| Total pasivo | US$3.12b |
| Activos totales | US$10.60b |
Actualizaciones recientes sobre salud financiera
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Sep 08
Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Apr 18Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Nov 20We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Aug 21Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?
May 23Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Feb 10Recent updates
A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Nov 04Bio-Rad Laboratories: Overvalued Given Current Growth Prospects
Sep 23We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Sep 08Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Shares May Have Run Too Fast Too Soon
Jul 18Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar
Jul 14Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Apr 18Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Apr 14At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?
Feb 07Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?
Dec 17Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Nov 20Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance
Oct 25At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?
Oct 02We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Aug 21Bio-Rad: A Cash Flow Returns On Investments Analysis
Aug 10Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?
Jul 30Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 04Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?
May 23A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
May 01Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Apr 04Bio-Rad Labs reports Q4 2022 results
Feb 16Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Feb 10Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jan 20Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals
Jan 04Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Dec 08Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M
Oct 27A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Oct 14Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal
Oct 12Bio-Rad Laboratories hits 52-week low; down 40% YTD
Sep 19Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Sep 02Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M
Jul 28When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 25Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jul 04Bio-Rad Laboratories (NYSE:BIO) Has A Rock Solid Balance Sheet
May 02Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($3.1B) de BIO superan a sus pasivos a corto plazo ($497.9M).
Pasivo a largo plazo: Los activos a corto plazo de BIO ($3.1B) superan a sus pasivos a largo plazo ($2.6B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: BIO tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de BIO ha crecido de 8.3% a 15.9% en los últimos 5 años.
Cobertura de la deuda: La deuda de BIO está bien cubierta por el flujo de caja operativo (34.6%).
Cobertura de intereses: BIO gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.